ElevateBio Raises $401M in Series D Financing
Summary
ElevateBio, a Waltham, MA-based technology company focused on powering the creation of life-transforming cell and gene therapies, raised $401M in Series D funding. Led by CEO David Hallal, ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies. Its integrated technologies model offers scale and biotechnological capabilities to power cell and gene therapy processes, programs and companies to their full potential. The company intends to use the funds to further advance its technology platforms Life Edit and BaseCamp. In connection with Novo Nordisk’s investment in the Series D financing, ElevateBio’s integrated subsidiary Life Edit Therapeutics also announced a multi-target collaboration with Novo Nordisk to discover and develop base editing therapies.